Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What do you think that will mean for shareholders, in your opinion? Worst and best case scenarios
catfish try this link.http://www.cardiumthx.com/media.html
Catfish, check out the matrix and aware trial news. I hope this link works.
http://www.cardiumthx.com/videos_aware.html
DOPEY621,I am holding CXM shares and plan to buy more. The reasons are GENREX and http://www.cardiumthx.com/videos_aware.html. Things are looking good to me and I shall hold and wait for the results.
What Are the Health Benefits of Sesame Oil?
TEXT SIZE: | POST A COMMENT | PRINT | SEND TO FRIEND |
SHARE
3
Sesame oil is pressed from the tiny sesame seed. There are numerous compounds and antioxidants within the sesame seed that are imparted into the oil. According to the Thomas Jefferson Agricultural Institute, sesame seeds are so beneficial that even after they have been pressed and the oil has been drained, the seed hulls can be fed to livestock. Although the oil is primarily used for dietary consumption, it's also a desired ingredient in cosmetics due to its high antioxidant content.
Lower Blood Pressure
Sesame oil has a lowering effect on blood pressure and levels of sodium in the blood. A study done in India and reported in the Yale Journal of Biology and Medicine shows that when subjects with high blood pressure were asked to consume sesame oil for 45 days, their blood pressure returned to normal readings. It was also documented that the research subjects lost weight while undergoing the addition of sesame oil. The effects were temporary, however. When the participants stopped taking the sesame oil, their blood pressure readings went back up. This could be in part to the fact that the sesame oil lowered sodium content in the body, acting as a diuretic.
To enjoy the benefits of lower blood pressure, make a commitment to make sesame oil a daily part of your diet. If you're on medication for blood pressure, be sure to speak with your physician first.
Sponsored Links
Cholesterol Diet
Have High Cholesterol? Find Low Cholesterol & Low Fat Diet Tips Now
Gi-Care.com
Lower Blood Sugar
Sesame oil also is good for blood sugar levels. A report in the Journal of Medicinal Foods labeled sesame oil as having an influence on the lowering of glucose. In the study, rats with diabetes were split up and some were fed sesame oil; the other group was not. The group fed the sesame oil had a significant decrease in blood sugar levels, and had an increase in antioxidant compounds in the blood.
Drizzling some sesame oil on a tossed salad, in place of olive oil, is a great way to add it to your diet to reap its health benefits.
Skin Benefits
The antioxidants in sesame oil impart benefits to the skin from the inside. It helps enhance the effects of vitamin E and other antioxidants, but it also benefits the skin when used on the outside. Anne McIntyre, a medical herbalist, published a report in Ayurveda on the benefits people see when using sesame oil on the skin. Those who use it have seen a decrease in skin infections and improvement in joint pain, due to the antibacterial and anti-inflammatory properties sesame oil contains. The report also states that the anti-cancer properties of sesame oil can be applied to the skin from the outside, as it has been shown to slow the development and growth of the skin cancer, melanoma.
To use sesame oil on the skin, Ayurvedic practice (a system of holistic medicine originating in India) recommends rubbing it all over the skin, then waiting 15 minutes before taking a hot shower or bath. As the oil soaks into the skin it has a detoxifying effect, and the warm water helps it soak in deeper.
Sponsored Links
As the markets whipsaw to changes in consumer sentiment, there will be weeks like this one, where we see gains that are exceptionally ahead of the pace of the movers and shakers of prior weeks. So before we get shaken out again, let's see why the CAPS community thinks some of these companies might continue to outperform the market.
A mighty temblor
Last week, Keryx Biopharmaceuticals (Nasdaq: KERX) caused a sensation when its colorectal cancer therapy, perifosine, received fast-track status from the FDA. However, the market's euphoria seems premature at best since drugs getting the fast-track designation often come up empty as they wind their way through phase 3 trials.
Yet AEterna Zentaris, which licenses perifosine to Keryx, is enjoying a coattails effect. CAPS member crj24 suggests AEterna is better-positioned than its licensee, as it has an exciting pipeline:
They have three drugs in phase 3, 3 in phase 2 and 3 in phase 1. Persifone will be FDA approved within a year. This stock will follow in Keryx footsteps untill after Persifone is approved. [Aeterna Zentaris] is better long term unless Keryx buys them out.
A buyout could indeed come, as Keryx might want to ensure sole access to the drug. A similar situation occurred this week and it's why Javelin Pharmaceuticals made the shakers cut. Hospira (NYSE: HSP) agreed to purchase the pharmaceutical company to ensure it wouldn't miss out on Javelin's nonopioid analgesic, Dyloject, which is used in pain management.
AEZS should move up as the ASCO meeting nears.
http://www.busystock.com/i.php?s=AEZS
Related Quotes
Sym. Price Chg.
CXM Trade
News 0.58 0.0025 Stock Alert for Cardium Therapeutics Inc. Issued by MicroStockProfit
Apr 30, 2010 06:52:43 (ET)
DALLAS, Apr 30, 2010 (GlobeNewswire via COMTEX) -- MicroStockProfit.com announces an investment report featuring Cardium Therapeutics Inc. (CXM, Trade ). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/CXM
Cardium Therapeutics Inc. (CXM) focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs and definable pathways to partnering, commercialization and other monetizations. Its investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of therapeutic products for wound healing, bone repair and cardiovascular indications. In July 2009, the Company completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.
Message Board Search for CXM: http://www.boardcentral.com/boards/CXM
In the report, the analyst notes:
"Consistent with its long-term strategy, CXM has stated that it intends to consider various corporate development transactions designed to place its product candidates into larger organizations or with partners having existing commercialization, sales and marketing resources, and a need for innovative products."
"In its report last month, CXM announced its agreement with bioRASI, an international contract research organization, to assist the Company in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures."
To read the entire report visit: www.microstockprofit.com/ads/CXM
See what investors are saying about CXM at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: MicroStockProfit.com
CONTACT: MicroStockProfit.com
Brian Johnson
1-888-307-2850
info@microstockprofit.com
ZZ is STOCKGOODIES a free siteor a pay?
BRIEFS
TUESDAY FEATURES
POSTS COMMENTS
You are here: Home / Briefs / QLT has positive outcomes treating LCA
QLT has positive outcomes treating LCA
April 20, 2010 by stephenkilmer · Leave a Comment
QLT (NASDAQ:QLTI; TSX:QLT (6.29 ?0.79%)) has released “positive outcomes” from interim results of the first three subjects enrolled in a Phase 1b clinical proof-of-concept study of its QLT091001 treatment for Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease.
LCA leads to retinal dysfunction and significant visual impairment beginning at birth. Based on the positive results from the first two pediatric patients, a protocol exception was granted to also treat an adult patient. QLT091001 is an oral synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.
QLT said that after seven days of treatment, the first three patients all experienced “clinically relevant improvements” in one or more visual function parameters and “meaningful improvements” in their visual performance related to tasks of daily living.
The onset of visual changes was “rapid and there was progressive improvement beyond the seven days of treatment, with some effects persisting for up to four months after treatment was completed,” the company added.
“These preliminary results are very exciting, are better than expected, and provide a measure of hope that a treatment might be developed for this devastating disease,” Dr. Robert Koenekoop, Director of the McGill Ocular Genetics Laboratory and Chief of Pediatric Ophthalmology at Montreal Children’s Hospital, said in a statement.
He looks good. he has completed more than 200 transactions involving $50 billion of principal investments, mergers, acquisitions, restructurings, and debt and equity financings. I like that part and would like to see a takeover of IPAS..
IPASS INC. needs to work on earnings not a R/S. The outstanding is 62,350,232 and the float is 41,341048. The R/S will not hold the price up but earnings will.
Did anyone see the RED FLAG that some thing was wrong with GNVC ? While you were doing your daily DD on the stocks you own you should have found this.http://events.jspargo.com/asco10/public/ExhibitorSearch.aspx
Where is GNVC ?
Augusta Masters Contest Pick" SPU
Amercian society of clinical oncology.http://chicago2010.asco.org/Home.aspx
Should help the bottom line.
SkyPeople Fruit Juice Engages Distributor of Hedetang(R)-branded Fruit Juice Beverages in Beijing
Sales to distributor expected to contribute $7.0 million in sales in 2010
XI'AN, China, Jan. 11 /PRNewswire-Asia-FirstCall/ -- SkyPeople Fruit Juice, Inc. (NYSE Amex: SPU) ("SkyPeople" or "the Company"), a processor and manufacturer of concentrated kiwifruit, apple, pear and other fruit juices and fruit products in China, today announced the engagement of a general distributor in Beijing to focus on the sales and marketing of the Company's Hedetang(R)-branded fruit juice beverages to food and beverage whole-sellers and retailers in the Beijing area.
On January 7, SkyPeople Fruit engaged a well-established beverage distributor to develop sales and brand recognition of the Company's Hedetang(R)-branded fruit juices in the nation's capital. Previously, the Company has primarily relied on its own sales force to sell Hedetang(R)-branded fruit juice primarily in the greater Xi'an area. The distributor has been appointed to sell the Company's Hedetang(R)-branded fruit juices to major retailers such as Wal-Mart, Jiale, Lotus and KA Supermarkets, as well as other whole-sellers in the Beijing area. The distribution agreement with SkyPeople includes a minimum sales commitment by the distributor on a monthly and yearly basis. Based on such commitment, the Company expects to generate sales of approximately US$7.0 million in 2010 under this distribution agreement.
"The entry into this distribution relationship is important to us in several aspects," said Mr. Yongke Xue, Chairman of SkyPeople. "First, it signals an important adjustment of our product mix to increase the relative percentage of sales of our Hedetang(R)-branded fruit juice beverages as compared to that of fruit juice concentrate. We believe there is a large domestic market potential for fruit juice beverages because of the expanding size of the Chinese middle class and the increasing awareness of healthy lifestyle. Further, we believe prices of our branded fruit juice beverages are generally less susceptible to general market conditions than those of our fruit juice concentrate. Secondly, entering "tier one" cities in China is a significant step for building the brand recognition of our Hedetang(R)-branded fruit juice beverages and is consistent with our objectives to position Hedetang(R) as high-quality kiwifruit, mulberry, apple and pear fruit juice beverages. Third, by entering into a distribution relationship with a well-established distributor in Beijing, we are further expanding our sales network. Beijing was the first on our short list of objectives which include all of tier one cities in China; Beijing, Shanghai and Guangzhou. Our Hedetang(R)-brand of fruit juices beverages are gaining market interest with target customers and the sheer size and demand of tier one cities will significantly contribute to our top and bottom lines in 2010 and beyond. Adjusting our product mix, building our brand recognition, diversifying our customer base, building sales network and expanding into untapped sales territories in China are the top priorities of our sales and marketing efforts this year. Our goal is to increase sales of our Hedetang(R) branded fruit juice beverages from approximately 12% in 2008 to 50% of sales in the next three years," Xue concluded.
Coconut oil health benefits.
http://products.mercola.com/coconut-oil/
EnteroMedics Announces Submission of IDE Application for Maestro RC System
Buzz up! 0
Print
Companies:EnteroMedics, Inc.
Related Quotes
Symbol Price Change
ETRM 0.61 0.00
Press Release Source: EnteroMedics Inc. On Monday March 15, 2010, 4:01 pm EDT
ST. PAUL, MN--(Marketwire - 03/15/10) - EnteroMedics Inc. (NASDAQ:ETRM - News), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has submitted an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA) for the Company's next-generation Maestro® RC System in the treatment of morbid obesity using VBLOC® vagal blocking therapy. The submission is the first step in the iterative IDE review process in support of a possible Premarket Approval (PMA) application.
"This IDE submission marks an important next step in advancing our Maestro RC System toward a pivotal study in obesity," said President and CEO Mark B. Knudson, Ph.D. "We look forward to working through the IDE review process with the FDA. We expect to be in a position to provide an update on our strategy after this process has reached a conclusion."
About EnteroMedics Inc.
EnteroMedics is a development stage medical device company focused on the design and development of devices that use neuroblocking technology to treat obesity and other gastrointestinal disorders. EnteroMedics' proprietary neuroblocking technology, VBLOC ® vagal blocking therapy, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. These electrical impulses are delivered by a neuroregulator which is powered either by an external controller (Maestro RF System) or an integrated rechargeable battery (EnteroMedics' next-generation Maestro RC System). EnteroMedics is currently conducting a feasibility study examining VBLOC Therapy's effects on blood glucose levels in diabetic patients outside of the United States. For more information, visit www.enteromedics.com.
WALNUTS
alnut consumption may improve endothelial function in Type 2 diabetics
By Helen Albert
05 February 2010
Diabetes Care 2010; 33: 227–232
MedWire News: A small exploratory study suggests that walnut consumption may improve endothelium-dependent vasodilation in individuals with Type 2 diabetes.
The findings provide further evidence that eating walnuts may have vascular benefits. Previous studies reported by MedWire News have demonstrated beneficial effects on serum lipids.
For this study, David Katz (Yale University School of Medicine, Derby, Connecticut, USA) and colleagues recruited 24 individuals with Type 2 diabetes aged 58 years on average.
They randomly assigned the participants to consume their normal diet (controls) or their normal diet plus 56 g (366 kcal) walnuts per day for a period of 8 weeks. After the first 8 weeks, all participants went through an 8-week washout period before swapping to the opposite diet for another 8 weeks.
All individuals initially underwent a 4-week run-in period to allow for diet and weight stabilization, during which time no walnuts or vasoactive medication or supplements were consumed.
Endothelial function testing was carried out by the researchers using flow-mediated dilation (FMD).
They found that FMD was significantly improved in the walnut supplemented group versus controls at study completion, by 2.2% versus 1.2%.
Total and low-density lipoprotein cholesterol were also reduced in the walnut supplemented group by 9.7 and 7.7 mg/dl (0.25 and 0.20 mmol/l), respectively, but these reductions were not statistically significant compared with controls.
Of note, anthropometric measures, glycated hemoglobin, and insulin sensitivity did not change significantly in the walnut supplemented group versus controls.
Writing in the journal Diabetes Care, the authors conclude: “Despite its limitations, this study provides evidence that regular walnut consumption improves endothelial function in Type 2 diabetic individuals and may therefore help reduce cardiovascular disease risk in this high-risk population.”
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010
Free abstract
Orion Party Bash MLK Day Contest Pick TSTF
Orion Party Bash MLK Day Contest Pick: HPCO
Quinoa and your health
http://www.naturalfoodbenefits.com/display.asp?CAT=6&ID=112
Labopharm(DDSS Quote)
Drug/indication: Trazodone Contramid for depression
FDA approval decision date: Feb. 11, 2010
Jut read company notes... Just change your name and start a new SCAM!
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=hcei
Lowtrader, It's nice to see you back.
DDSS is due for FDA approval on 2/11/2010 or disapproval.
what is your thoughts on this play an price range?
tia
Dose anyone have info on trial NCT00868114? TNFerafe was part of this trial.
http://www.clinicaltrials.gov/ct2/show/NCT00868114?term=NCT00868114&rank=1
TIA
anotherboat,I am invested in GNVC with the rest of the gang. GNVC will move up when FDA approval is granted... Daily pumping won"t help just hang on for the ride in the future...
Take some time and listen to the message in this video. Fda approval may take 8 months or more but the wait will be worth it.
MCKINLEY MORGANFIELD, ? Is TNFerade only a GNVC item?? I see another company is doing a phase2 direct injection with TNFerade. Things are moveing along with GNVC but FDA approval will take some time.
tia